SciSparc's MitoCareX Shows Promise in Lung Cancer Treatment
Ticker: SPRC · Form: 6-K · Filed: Jul 23, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Jul 23, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: drug-development, oncology, press-release
TL;DR
SciSparc's drug target MitoCareX shows potential for Non-Small Cell Lung Cancer, a big deal for cancer treatment.
AI Summary
On July 22, 2024, SciSparc Ltd. announced that its drug target, MitoCareX, has shown potential in treating Non-Small Cell Lung Cancer (NSCLC). This finding is based on research and development efforts by the company, aiming to address a significant unmet need in cancer therapy.
Why It Matters
This development could lead to new treatment options for Non-Small Cell Lung Cancer, a major cause of cancer-related deaths, potentially improving patient outcomes.
Risk Assessment
Risk Level: medium — The announcement is based on preliminary findings and requires further clinical trials and regulatory approval, which carry inherent risks.
Key Players & Entities
- SciSparc Ltd. (company) — The company issuing the press release.
- MitoCareX (drug_target) — The drug target showing potential in cancer treatment.
- Non-Small Cell Lung Cancer (disease) — The type of cancer being targeted.
- July 22, 2024 (date) — Date of the press release.
FAQ
What is the specific role of MitoCareX in Non-Small Cell Lung Cancer as confirmed by SciSparc?
The press release indicates that MitoCareX has confirmed a potential significant role in Non-Small Cell Lung Cancer, suggesting it may be a key factor in the disease's progression or treatment.
When was this information about MitoCareX and lung cancer released by SciSparc?
The information was released in a press release on July 22, 2024.
What is the filing form and accession number for this SciSparc Ltd. report?
This is a Form 6-K with accession number 0001213900-24-063307.
What is SciSparc Ltd.'s primary business sector?
SciSparc Ltd. is in the Pharmaceutical Preparations sector, SIC code 2834.
What is the principal executive office address for SciSparc Ltd.?
The principal executive offices are located at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel.
Filing Stats: 321 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2024-07-23 07:33:41
Filing Documents
- ea0209790-6k_scisparc.htm (6-K) — 12KB
- ea020979001ex99-1_scisparc.htm (EX-99.1) — 9KB
- 0001213900-24-063307.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: July 23, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3